Leucovorin + 5-fluorouracil plus dipyridamole in leucovorin + 5-fluorouracil-pretreated patients with advanced colorectal cancer: a pilot study of three different dipyridamole regimens
| Autor: | Kostadinos Fotiadis, M. Vadiaka, Panagiotis Vachiotis, Nicolas Tsavaris, Sofia Rokana, Kostadinos Genatas, Christos Kosmas, A. Dimitrakopoulos, Aristidis Polyzos, G Karatzas, Platon Paliaros |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
0301 basic medicine
Male Cancer Research medicine.medical_specialty Nausea medicine.medical_treatment 030106 microbiology Leucovorin Pilot Projects Neutropenia Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Mucositis Humans Saline Aged Chemotherapy business.industry General Medicine Dipyridamole Middle Aged medicine.disease Oncology Fluorouracil 030220 oncology & carcinogenesis Toxicity Female medicine.symptom business Colorectal Neoplasms medicine.drug |
| Zdroj: | Tumori. 87(5) |
| ISSN: | 0300-8916 |
| Popis: | Dipyridamole, an inhibitor of nucleoside transport, increases the activity of 5-fluorouracil in a dose-dependent manner. The purpose of the present study was to determine whether dipyridamole with 5-fluorouracil and leucovorin gave an improved therapeutic outcome. Sixty patients entered in the present pilot study had previously received 5-fluorouracil (450 mg/m2) and leucovorin (100 mg/m2), every week, and relapsed during this treatment, which ended at least 6 weeks prior to study entry. Dipyridamole was administered at three different dosing schedules (DS) and methods of administration in three groups of patients. DS I: dipyridamole, 30 mg/m2 in normal saline solution, in 90 min iv infusion, followed by leucovorin, 100 mg/m2 iv push, followed by 5-fluorouracil, 450 mg/m2 in normal saline solution, in 60 min iv infusion, dipyridamole tablets (75 mg) every 12 hrs, continuously during the time of chemotherapy. DS II: dipyridamole, 50 mg/m2 in normal saline solution, in 90 min iv infusion, and the rest was the same as DS I. DS III: without oral dipyridamole, patients received dipyridamole (50 mg/m2) iv in the same manner as in DS I and II. Treatment was continued until tumor progression or unacceptable toxicity. All patients (n = 60) entered in the present study were assessable for response and toxicity. No complete response was observed. No patient at DS I responded, whereas 2 patients at DS II and 3 at DS III had a partial response (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|